Target- |
Mechanism- |
|
|
Active Indication- |
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.US |
First Approval Date15 Jul 1941 |
甲萘氢醌二磷酸酯钠片单中心、随机、开放I期人体药代动力学试验
[Translation] A single-center, randomized, open-label phase I pharmacokinetic trial of menadione sodium diphosphate tablets in humans
考察健康人对甲萘氢醌二磷酸酯钠片的药代动力学特征,为制定本品的Ⅱ期临床试验提供依据。
[Translation] To investigate the pharmacokinetic characteristics of sodium menadione diphosphate tablets in healthy subjects and provide a basis for the formulation of Phase II clinical trials of this product.
甲萘氢醌二磷酸酯钠片治疗获得性维生素K依赖性凝血因子缺乏症的有效性和安全性研究
[Translation] Efficacy and safety of menadione diphosphate sodium tablets in the treatment of acquired vitamin K-dependent coagulation factor deficiency
以醋酸甲萘氢醌片为对照,评价甲萘氢醌二磷酸酯钠片治疗获得性维生素K依赖性凝血因子缺乏症的有效性和安全性。
[Translation] To evaluate the efficacy and safety of menadione diphosphate sodium tablets in the treatment of acquired vitamin K-dependent coagulation factor deficiency, using menadione acetate tablets as a control.
100 Clinical Results associated with Wuxi Jialing Medicine Co., Ltd.
0 Patents (Medical) associated with Wuxi Jialing Medicine Co., Ltd.
100 Deals associated with Wuxi Jialing Medicine Co., Ltd.
100 Translational Medicine associated with Wuxi Jialing Medicine Co., Ltd.